Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure

Fig. 2

DOX AUC and cmax depending on age (a, b), body composition (c, d), and treatment regimen (e, f). For (ab) children on the 50th percentile of body height and weight were simulated and for (cd) children aged 1 year were simulated. The DOX dose was adopted from the CWS-guidance and doses were reduced in children < 6 months to 67% of the body weight-based dose and in children 6–12 months or < 10 kg to 100% of the body weight-based dose (see Additional file 1). For (e, f) a median 2-year-old child was simulated (for doses and infusion times see Additional file 1). To display the remaining inter-individual variability that cannot be attributed to the influence of age or body surface area simulations were replicated 1000 times

Back to article page